Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Asthma Medicine & Life Sciences
Papillomavirus Infections Medicine & Life Sciences
Uveitis Medicine & Life Sciences
Visual Acuity Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences
Steroids Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2017

Fluocinolone Acetonide
Panuveitis
Visual Acuity
Anti-Inflammatory Agents
Therapeutics

Effectiveness of two distinct web-based education tools for bedside nurses on medication administration practice for venous thromboembolism prevention: A randomized clinical trial

Lau, B. D., Shaffer, D. L., Hobson, D. B., Yenokyan, G., Wang, J., Sugar, E. A., Canner, J. K., Bongiovanni, D., Kraus, P. S., Popoola, V. O., Shihab, H. M., Farrow, N. E., Aboagye, J. K., Pronovost, P. J., Streiff, M. B. & Haut, E. R. 2017 In : PloS one. 12, 8, p. e0181664

Research output: Research - peer-reviewArticle

randomized clinical trials
nurses
drug therapy
education
Venous Thromboembolism

Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy

Sugar, E. A., Venugopal, V., Thorne, J. E., Frick, K. D., Holland, G. N., Wang, R. C., Almanzor, R., Jabs, D. A. & Holbrook, J. T. Jan 6 2017 (Accepted/In press) In : Ophthalmology.

Research output: Research - peer-reviewArticle

Fluocinolone Acetonide
Uveitis
Adrenal Cortex Hormones
Quality of Life
Therapeutics

Reproducibility of airway luminal size in asthma measured by HRCT

Brown, R. H., Henderson, R. J., Sugar, E. A., Holbrook, J. T. & Wise, R. A. Oct 1 2017 In : Journal of Applied Physiology. 123, 4, p. 876-883 8 p.

Research output: Research - peer-reviewArticle

Asthma
Lung
Total Lung Capacity
Continuous Positive Airway Pressure
Functional Residual Capacity

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

Hanley, D. F. , Lane, K. , McBee, N. , Ziai, W. , Tuhrim, S. , Lees, K. R. , Dawson, J. , Gandhi, D. , Ullman, N. , Mould, W. A. , Mayo, S. W. , Mendelow, A. D. , Gregson, B. , Butcher, K. , Vespa, P. , Wright, D. W. , Kase, C. S. , Carhuapoma, J. R. , Keyl, P. M. , Diener-West, M. & 22 others Muschelli, J., Betz, J. F., Thompson, C. B., Sugar, E. A., Yenokyan, G., Janis, S., John, S., Harnof, S., Lopez, G. A., Aldrich, E. F., Harrigan, M. R., Ansari, S., Jallo, J., Caron, J. L., LeDoux, D., Adeoye, O., Zuccarello, M., Adams, H. P., Rosenblum, M., Thompson, R. E., Awad, I. A. & CLEAR III Investigators Feb 11 2017 In : The Lancet. 389, 10069, p. 603-611 9 p.

Research output: Research - peer-reviewArticle

Tissue Plasminogen Activator
Stroke
Placebos
Hemorrhage
Therapeutics